Press Releases - Renalytix

MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities

07.17.25

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with kidneyintelX.dkd , the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, and MVP Health Care ("MVP") , a not-for-profit health insurer that provides services to 700,000 members in the northeastern part of the United States, have joined forces to mitigate the progression of chronic kidney disease in their insured type 2 diabetes patient population.

Growing collaboration with NYKHM

06.03.25

LONDON and NEW YORK, 3 June 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company, announces a collaboration with New York Kidney & Hypertension Medicine (NYKHM) to expand access to kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in patients with type 2 diabetes and chronic kidney disease stages 1-3b.

Commencement of trading on OTCQB in the United States

10.08.24

Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

07.11.24

LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

06.27.24

Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

06.14.24

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on June 13,

Management Change

05.29.24

LONDON and SALT LAKE CITY - 28 May 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that O. James Sterling will step down from his role as Chief Financial Officer of the Company as of 24 May 2024 and will remain at the Company until 10 June 2024. The Board has appointed Joel R. Jung as Interim Chief Financial Officer, effective immediately while a handover period takes place.

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

05.15.24

LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today

Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

05.09.24

LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live

Management Change

04.18.24

LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “ Ordinary Shares ”) (the “